PDCD1 and cancer: To reinvigorate the antitumor activity of exhausted T cells, the FDA has approved three PD-1 blocking antibodies (nivolumab [Opdivo], pembrolizumab [Keytruda], and cemiplimab [Libtayo]) for various cancer indications [17, 19].